拓扑替康单药治疗难治性小细胞肺癌的临床评价  

Clinical evaluation of topotecan in treatment of patients with hard-cured small cell lung cancer

作　　者：高文斌 尹良伟 王怀瑾 王丽双 王蕾 

机构地区：[1]大连市肿瘤医院肿瘤五病区

出　　处：《中国临床药理学与治疗学》2003年第5期585-587,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的 :观察拓扑替康单药治疗难治性小细胞肺癌 (SCLC)的疗效及其毒副反应。方法 :难治性SCLC患者 3 8例 ,采用拓扑替康 (topotecan,T ,金喜素 ) 1 .2mg·m- 2 ·d- 1 ,静脉滴注 ,d1～ 5,2 1d为 1个周期 ,共 2～ 3个周期。结果 :拓扑替康单药的有效率为 2 3 .68% (9 3 8) ,其中局限型病例的有效率为3 6.3 6% (4 1 1 ) ,广泛型为 1 8.5 2 % (5 2 7) ,组间比较无统计学差异 (χ2 =0 .5 67,P >0 .0 5 )。毒副反应以血液毒性为主 ,白细胞和血小板Ⅲ +Ⅳ度下降病例为 2 3 .68% ,2 6.3 2 % ,血红蛋白未见明显的毒副反应 ,其他反应轻微。结论 :拓扑替康单药治疗难治性SCLC具有较好的疗效并可以作为SCLC的二线治疗药物应用。AIM: To observe the efficacy and safety of topotecan on hard cured small cell lung cancer (SCLC). METHODS: 38 patients of hard cured SCLC were treated with topotecan 1.2 mg·m -2 ·d -1 (iv) on d 1～5 and 21 days a cycle and the treatment lasted for 2-3 cycles. RESULTS: The response rate to topotecan was 23.68 % (9/38) including 36.36 % (4/11) in limited type and 18.52 % (5/27) in extensive type. There were no statistical differences between them (χ 2= 0.567 ,P> 0.05 ). The main side reactions were neutropenia and thrombocytopenia with incidence of 23.68 % and 26.32 % in grade Ⅲ+Ⅳ, respectively, but without side reaction to hemoglobin. CONCLUSION: Topotecan is an effective agent in the treatment of patients with SCLC.

关 键 词：药效学 拓扑替康 小细胞肺癌 难治性 化疗 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]